Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

. 2022 Jan ; 10 (1) : .

Jazyk angličtina Země Velká Británie, Anglie Médium print

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid34992091

BACKGROUND: Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2. METHODS: Patients with International Federation of Gynecology and Obstetrics stage III EOC (serous, endometrioid, or mucinous), who underwent cytoreductive surgery up to 3 weeks prior to randomization and were scheduled for first-line platinum-based CT were eligible. Patients, stratified by tumor residuum (0 or <1 cm), were randomized (1:1:1) to DCVAC/OvCa parallel to CT (Group A), DCVAC/OvCa sequential to CT (Group B), or CT alone (Group C) in Part 1, and to Groups B and C in Part 2. Autologous dendritic cells for DCVAC were differentiated from patients' CD14+ monocytes, pulsed with two allogenic OvCa cell lines (SK-OV-3, OV-90), and matured in the presence of polyinosinic:polycytidylic acid. We report the safety outcomes (safety analysis set, Parts 1 and 2 combined) along with the primary (progression-free survival (PFS)) and secondary (overall survival (OS)) efficacy endpoints. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) analysis set in Part 1. RESULTS: Between November 2013 and March 2016, 99 patients were randomized. The mITT (Part 1) comprised 31, 29, and 30 patients in Groups A, B, and C, respectively. Baseline characteristics and DCVAC/OvCa exposure were comparable across the treatment arms. DCVAC/OvCa showed a good safety profile with treatment-emergent adverse events related to DCVAC/OvCa in 2 of 34 patients (5.9%) in Group A and 2 of 53 patients (3.8%) in Group B. Median PFS was 20.3, not reached, and 21.4 months in Groups A, B, and C, respectively. The HR (95% CI) for Group A versus Group C was 0.98 (0.48 to 2.00; p=0.9483) and the HR for Group B versus Group C was 0.39 (0.16 to 0.96; p=0.0336). This was accompanied by a non-significant trend of improved OS in Groups A and B. Median OS was not reached in any group after a median follow-up of 66 months (34% of events). CONCLUSIONS: DCVAC/OvCa and leukapheresis was not associated with significant safety concerns in this trial. DCVAC/OvCa sequential to CT was associated with a statistically significant improvement in PFS in patients undergoing first-line treatment of EOC. TRIAL REGISTRATION NUMBER: NCT02107937, EudraCT2010-021462-30.

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. 10.3322/caac.21660 PubMed DOI

Ledermann JA, Raja FA, Fotopoulou C, et al. . Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi24–32. 10.1093/annonc/mdt333 PubMed DOI

Galluzzi L, Chan TA, Kroemer G, et al. . The hallmarks of successful anticancer immunotherapy. Sci Transl Med 2018;1010.1126/scitranslmed.aat7807 PubMed DOI

Wculek SK, Cueto FJ, Mujal AM, et al. . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 2020;20:7–24. 10.1038/s41577-019-0210-z PubMed DOI

Boudousquié C, Boand V, Lingre E, et al. . Development and optimization of a GMP-compliant manufacturing process for a personalized tumor lysate dendritic cell vaccine. Vaccines 2020;8:25. 10.3390/vaccines8010025 PubMed DOI PMC

Chiang CL-L, Kandalaft LE, Tanyi J, et al. . A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013;19:4801–15. 10.1158/1078-0432.CCR-13-1185 PubMed DOI PMC

Harari A, Graciotti M, Bassani-Sternberg M, et al. . Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov 2020;19:635–52. 10.1038/s41573-020-0074-8 PubMed DOI

Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in ovarian cancer: are we there yet? J Clin Oncol 2019;37:2460–71. 10.1200/JCO.19.00508 PubMed DOI

Sarivalasis A, Boudousquié C, Balint K, et al. . A phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. J Transl Med 2019;17:391. 10.1186/s12967-019-02133-w PubMed DOI PMC

Tanyi JL, Bobisse S, Ophir E, et al. . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med 2018;1010.1126/scitranslmed.aao5931 PubMed DOI

Fucikova J, Moserova I, Truxova I, et al. . High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 2014;135:1165–77. 10.1002/ijc.28766 PubMed DOI

Fučíková J, Rožková D, Ulčová H, et al. . Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011;9:223. 10.1186/1479-5876-9-223 PubMed DOI PMC

Keskin DB, Anandappa AJ, Sun J, et al. . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 2019;565:234–9. 10.1038/s41586-018-0792-9 PubMed DOI PMC

Westdorp H, Creemers JHA, van Oort IM, et al. . Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother Cancer 2019;7:302. 10.1186/s40425-019-0787-6 PubMed DOI PMC

Podrazil M, Horvath R, Becht E, et al. . Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2015;6:18192–205. 10.18632/oncotarget.4145 PubMed DOI PMC

Fucikova J, Podrazil M, Jarolim L, et al. . Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. Cancer Immunol Immunother 2018;67:89–100. 10.1007/s00262-017-2068-x PubMed DOI PMC

Podrazil M, Rožková D, Hromádková H. Ovarian cancer immunotherapy – clinical trial. poster presented at: 13th annual meeting of the Federation of clinical immunology societies. Boston, USA, 2013.

Gynecologic Cancer InterGroup (GCIG) . CA 125 definitions agreed by GCIG November 2005. Available: https://gcigtrials.org/system/files/CA%20125%20Definitions%20Agreed%20to%20by%20GCIG%20-%20November%202005.pdfhttps://doi.org/ [Accessed 16 Mar 2021].

Clarke B, Tinker AV, Lee C-H, et al. . Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22:393–402. 10.1038/modpathol.2008.191 PubMed DOI

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, et al. . Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 2017;3:e173290. 10.1001/jamaoncol.2017.3290 PubMed DOI PMC

Hwang W-T, Adams SF, Tahirovic E, et al. . Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192–8. 10.1016/j.ygyno.2011.09.039 PubMed DOI PMC

Sato E, Olson SH, Ahn J, et al. . Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538–43. 10.1073/pnas.0509182102 PubMed DOI PMC

Galluzzi L, Humeau J, Buqué A, et al. . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 2020;17:725–41. 10.1038/s41571-020-0413-z PubMed DOI

Petroni G, Buqué A, Zitvogel L, et al. . Immunomodulation by targeted anticancer agents. Cancer Cell 2021;39:310–45. 10.1016/j.ccell.2020.11.009 PubMed DOI

Baek S, Kim Y-M, Kim S-B, et al. . Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol 2015;12:87–95. 10.1038/cmi.2014.40 PubMed DOI PMC

Bapsy PP, Sharan B, Kumar C, et al. . Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy 2014;16:234–44. 10.1016/j.jcyt.2013.11.013 PubMed DOI

Chu CS, Boyer J, Schullery DS, et al. . Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012;61:629–41. 10.1007/s00262-011-1081-8 PubMed DOI PMC

Kandalaft LE, Chiang CL, Tanyi J, et al. . A phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med 2013;11:149. 10.1186/1479-5876-11-149 PubMed DOI PMC

Loveland BE, Zhao A, White S, et al. . Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12:869–77. 10.1158/1078-0432.CCR-05-1574 PubMed DOI

Rahma OE, Ashtar E, Czystowska M, et al. . A gynecologic Oncology Group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012;61:373–84. 10.1007/s00262-011-1100-9 PubMed DOI PMC

Sabbatini P, Tsuji T, Ferran L, et al. . Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012;18:6497–508. 10.1158/1078-0432.CCR-12-2189 PubMed DOI

Somaiah N, Block MS, Kim JW, et al. . First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. Clin Cancer Res 2019;25:5808–17. 10.1158/1078-0432.CCR-19-1025 PubMed DOI

Zhang W, Lu X, Cui P, et al. . Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother 2019;68:121–30. 10.1007/s00262-018-2257-2 PubMed DOI PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02107937

Najít záznam

Citační ukazatele

Možnosti archivace